Jump to

Quality Control

Batch: Purity: 99.81%

99.81

Related Targets	PD-1/PD-L1 CXCR STING AhR CD markers Interleukins Anti-infection Antioxidant COX Histamine Receptor
Other Immunology & Inflammation related Inhibitors	Cl-amidine Bestatin (Ubenimex) Bindarit (AF 2838) Tranilast GI254023X (GI4023) Sinomenine Geniposidic acid CORM-3 Germacrone Oxymatrine

Solubility

In vitro
Batch:

DMSO : 35 mg/mL (203.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 35 mg/mL

Ethanol : 35 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	Saline Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	30.000mg/ml (174.18mM)	Taking the 1 mL working solution as an example, add 30 mg of this product to 1 ml of physiological saline (0.9% NaCL solution), mix evenly to make it clear, The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	172.24	Formula	C₉H₁₈NO₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	2226-96-2	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	4-Hydroxy-TEMPO			SMILES	CC1(CC(CC(N1[O])(C)C)O)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro	Tempol (4-Hydroxy-TEMPO) is a stable, cell-permeable nitroxide that acts as a free radical scavenger and nitric oxide spin trap. This compound exhibits radio-protective and anti-proliferative properties. It inhibits oxygen-dependent radiation-induced damage. It induces oxidative stress and enhances the levels of p21WAF1 in HL-60 cells in a dose-dependent manner.
In vivo	Tempol reduces oxidant stress-mediated renal dysfunction and injury in the rat. This compound prevents cerebral vessel remodeling in hypertensive rats. It lowers blood pressure and sympathetic nerve activity but not vascular O2- in DOCA-salt rats. It restores mitochondrial and cardiac functions in TNFα-induced oxidative stress and reduces cardiac hypertrophy in chronic hypoxic rats.
References	[1] https://pubmed.ncbi.nlm.nih.gov/1654848/ [2] https://pubmed.ncbi.nlm.nih.gov/11033415/ [3] https://pubmed.ncbi.nlm.nih.gov/10916089/ [4] https://pubmed.ncbi.nlm.nih.gov/20600163/ [5] https://pubmed.ncbi.nlm.nih.gov/14707156/ [6] https://pubmed.ncbi.nlm.nih.gov/17675574/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-12-09)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06424756	RECRUITING	Healthy	University of Georgia	2024-07-01	PHASE2
NCT03480971	RECRUITING	Mucositis; Nephrotoxicity; Ototoxicity	Matrix Biomed, Inc.	2019-05-13	PHASE2
NCT04729595	TERMINATED	Covid19	Adamis Pharmaceuticals Corporation	2021-09-01	PHASE2; PHASE3
NCT04876755	UNKNOWN	Prostate Cancer Recurrent; Biochemical Recurrent Prostate Cancer	Matrix Biomed, Inc.	2021-05-30	PHASE2
NCT04729595	Terminated	Covid19	Adamis Pharmaceuticals Corporation	2021-09-01	Phase 2\|Phase 3
NCT03680404	COMPLETED	Cardiovascular Diseases; Cardiovascular Risk Factor; Vasoconstriction	The University of Texas at Arlington	2018-10-01	PHASE1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Tempol Immunology & Inflammation related chemical

Chemical Structure

Molecular Weight: 172.24